The evolution of the cytokine profile under the influence of immunomodulator glutamine-cystine-glycine disodium in patients with destructive multidrug-resistant lung tuberculosis

Authors

  • E. N. Raznatovskaya

DOI:

https://doi.org/10.14739/2310-1210.2015.3.44508

Keywords:

Cytokines, Immunomodulator, Multidrug-resistant Tuberculosis

Abstract

Importance of the problem caused by the necessity of treatment efficiency improving in patients with multidrug-resistant destructive pulmonary tuberculosis (MDR).

Aim. To study the dynamics of cytokine profile indicators under the influence of immunomodulator Glutamyl-cysteinyl-glycine disodium (GCGD) controlled trial was conducted.

Methods and results. The study included 60 patients with destructive MDR: 30 patients were treated with implementation of GCGD on the basis of standard chemotherapy course and 30 patients were treated with standard chemotherapy course alone. Cytokine profile indicators were studied in serum by indirect ELISA method. It was found that the usage of immunomodulator GCGD in patients with destructive MDR allows to normalize cytokine profile indicators in 46.7 % of cases.

Conclusion. This data demonstrates the advisability of its using.

References

Cherenko, S. A. Problema khimiorezystentnoho tuberkulozu [Problem multidrug-resistant tuberculosis tuberculosis]. Retrieved from http://www.ifp.kiev.ua/doc/ people / tubrezist.htm. [in Ukrainian].

Feschenko, Y. I. (2011). Antybiotykorezystentnist mikroorhanizmiv. Stan problemy ta shliakhy yii vyrishennia [Antibiotic resistance of microorganisms. State the problem and ways to solve]. Ukrainskyi khimioterapevtychnyi zhurnal, 4, 41–43. [in Ukrainian].

Mishin, V. Yu., Komissarov, O. G., Chukanov, V. I. & Kononets, A. (2009). Osobennosti techeniya processa i e`ffektivnost' lecheniya bol'nykh tuberkulyozom lyogkikh, vydelyayuschikh mikobakterii tuberkulyoza s obshirnoj lekarstvennoj ustojchivost'yu k protivotuberkulyoznym preparatam [The course of a process and the efficiency of treatment of pulmonary tuberculosis patients excreting Mycobacterium tuberculosis with extensive drug resistance to antituberculous drugs]. Problemy tuberkuleza, 2, 50–51. [in Russian].

Platonova, I. L., Tkach, O. A., Sakhelashvili, M. I., Schurko, G. V., Lapovets, N. Ye. & Shtybel, G. D. (2011). Otsinka efektyvnosti antymikobakterialnoi terapii u khvorykh na tuberkuloz lehen za pokaznykamy imunolohichnykh doslidzhen [Evaluation of antimycobacterial therapy in patients with pulmonary tuberculosis on indicators of immunological research]. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia, 2, 21–25. [in Ukrainian].

Chernushenko, E. F. & Procyuk, R. G. (2010). Protivotuberkuleznyj immunitet (Chast' І) [Аntituberculous immunity (Part I)]. Ukrainskyi pulmonolohichnyi zhurnal, 4, 53–58. [in Ukrainian].

Chernushenko, E. F. & Procyuk, R. G. (2011). Protivotuberkuleznyj immunitet (Chast' ІІ) [Аntituberculous immunity (Part II)]. Ukrainskyi pulmonolohichnyi zhurnal, 1, 29–32. [in Ukrainian].

Feschenko, Yu. I., Ischuk, S. G. & Matvienko, Yu. A. (2012). Terapevticheskie vozmozhnosti innovacionnogo immunomodulyatora v pul'monologii i ftiziatrii [Therapeutic opportunities of innovative immunmodulator in pulmonology and phthisiology]. Ukrainskyi pulmonolohichnyi zhurnal, 3, 50–54. [in Ukrainian].

Balasanyants, G. S. & Sukhanov, D. S. (2011). Nekotorye aspekty patogeneti4eskoj terapii pri tuberkuleze v sovremennyh uslovijah [Current aspects of pathogenetic therapy in tuberculosis] Terapevniсрeskij arлhiv, 83(8), 21–24. [in Russian].

Antushevich, A. E., Antonov, V. G., Vasilenko, K. P. & Burova, E. B. (2005). Vozmozhnyj mekhanizm ustraneniya antibiotikorezistentnosti mikobakterij tuberkuleza preparatom glutoksim [A possible mechanism for eliminating antibiotic resistance of Mycobacterium tuberculosis glutoxim]. Innovacionnye tehnologii v medicine XXI v.: Abstracts of Papers of the First All-Russian Scientific Forum, (p. 405–407). [in Russian].

Peresi, E., Silva, S. M., Calvi, S. A., & Marcondes-Machado, J. (2008). Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. Jornal Brasileiro de Pneumologia, 11, 942–949. doi: http://dx.doi.org/10.1590/S1806-37132008001100009.

Downloads

How to Cite

1.
Raznatovskaya EN. The evolution of the cytokine profile under the influence of immunomodulator glutamine-cystine-glycine disodium in patients with destructive multidrug-resistant lung tuberculosis. Zaporozhye medical journal [Internet]. 2015Jun.15 [cited 2024Apr.19];17(3). Available from: http://zmj.zsmu.edu.ua/article/view/44508

Issue

No. 3 (2015): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)